Use of antidepressants and risk of lung cancer

Cancer Causes and Control

Volumn 18, Issue 10, 2007, Pages 1055-1064

  Toh, Sengwee ^a   García Rodríguez, Luis A ^b   Hernández Díaz, Sonia ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Pharmacoepidemiology   (Spain)

Author keywords

Antidepressive agents; Case control studies; Epidemiology; Lung neoplasms

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34848866314     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-007-9045-1     Document Type: Article

References (42)

1. Brandes LJ, Arron RJ, Bogdanovic RP et al (1992) Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52:3796-3800
2. Wright SC, Zhong J, Larrick JW (1994) Inhibition of apoptosis as a mechanism of tumor promotion. Faseb J 8:654-660
3. Eisen JN, Irwin J, Quay J, Livnat S (1989) The effect of antidepressants on immune function in mice. Biol Psychiatry 26:805-817
4. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ (2003) Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 3:169-184
5. Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM (1992) Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 52:6931-6935
6. Parchment RE, Machado S, Balch A et al (1992) Lack of stimulation of murine tumor growth by antidepressants and antihistamines (abstract). Proc Am Assoc Cancer Res 37:160
7. Abdul M, Logothetis CJ, Hoosein NM (1995) Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154:247-250
8. Freire-Garabal M, Nunez MJ, Pereiro D et al (1998) Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci 63:PL31-PL38
9. Serafeim A, Holder MJ, Grafton G et al (2003) Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212-3219
10. Rosetti M, Frasnelli M, Tesei A, Zoli W, Conti M (2006) Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. J Exp Ther Oncol 6:23-29
11. Harlow BL, Cramer DW (1995) Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States). Cancer Causes Control 6:130-134
12. Harlow BL, Cramer DW, Baron JA, Titus-Ernstoff L, Greenberg ER (1998) Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 7:697-702
13. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE (2000) Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med 22:155-160
14. Steingart A, Cotterchio M, Kreiger N, Sloan M (2003) Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 32:961-966
15. Cotterchio M, Kreiger N, Darlington G, Steingart A (2000) Antidepressant medication use and breast cancer risk. Am J Epidemiol 151:951-957
16. Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14:307-314
17. Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR (2006) Antidepressant use and breast cancer risk. Breast Cancer Res Treat 95:131-140
18. Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 162:835-838
19. Coogan PF, Rosenberg L, Palmer JR et al (2000) Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). Cancer Causes Control 11:839-845
20. Dublin S, Rossing MA, Heckbert SR, Goff BA, Weiss NS (2002) Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control 13:35-45
21. Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS (2006) Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 94:1071-1078
22. González-Pérez A, García Rodríguez LA (2005) Breast cancer risk among users of antidepressant medications. Epidemiology 16:101-105
23. Kelly JP, Rosenberg L, Palmer JR et al (1999) Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 150:861-868
24. Moorman PG, Berchuck A, Calingaert B, Halabi S, Schildkraut JM (2005) Antidepressant medication use [corrected] and risk of ovarian cancer. Obstet Gynecol 105:725-730
25. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J (2001) Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 54:728-734
26. Dalton SO, Johansen C, Mellemkjaer L et al (2000) Antidepressant medications and risk for cancer. Epidemiology 11:171-176
27. Xu W, Tamim H, Shapiro S, Stang MR, Collet JP (2006) Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol 7:301-308
28. Theoharides TC, Konstantinidou A (2003) Antidepressants and risk of cancer: a case of misguided associations and priorities. J Clin Psychopharmacol 23:1-4
29. Lawrenson RA, Tyrer F, Newson RB, Farmer RD (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59:149-157
30. Ornstein S, Stuart G, Jenkins R (2000) Depression diagnoses and antidepressant use in primary care practices: a study from the practice partner research network (PPRNet). J Fam Pract 49:68-72
31. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130
32. Hernández-Díaz S, García-Rodríguez LA (2007) Non-steroidal anti-inflammatory drugs and the risk of lung cancer. Int J Cancer 120:1565-1572
33. Psaty BM, Koepsell TD, Lin D et al (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749-754
34. Knekt P, Raitasalo R, Heliovaara M et al (1996) Elevated lung cancer risk among persons with depressed mood. Am J Epidemiol 144:1096-1103
35. Covey LS, Glassman AH, Stetner F (1998) Cigarette smoking and major depression. J Addict Dis 17:35-46
36. Klungsoyr O, Nygard JF, Sorensen T, Sandanger I (2006) Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. Am J Epidemiol 163:421-432
37. Cofta-Woerpel L, Wright KL, Wetter DW (2006) Smoking cessation 1: pharmacological treatments. Behav Med 32:47-56
38. Hughes JR, Stead LF, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No. CD000031
39. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA (2002) National trends in the outpatient treatment of depression. JAMA 287:203-209
40. Stafford RS, MacDonald EA, Finkelstein SN (2001) National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 3:232-235
41. Mittmann N, Herrmann N, Einarson TR et al (1997) The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 46:191-217
42. Song F, Freemantle N, Sheldon TA et al (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306:683-687